o date, hundreds of clinical trials have been conducted on dozens of already available drugs or natural/herbal substances to repurpose for the treatment of COVID-19, but with no consistent statistically significant positive results. Even, drugs such as hydroxychloroquine and Ivermectin that proved in some studies to be beneficial and thus included in many national guidelines for therapy, failed to keep their position after the release of negative results of further larger randomized comparative studies. This situation is still going on and a lot of studies with conflicting results are being published causing a lot of confusion. Remdesvir, after granting the FDA approval as the first drug approved for COVID-19, is facing such confusing situation, after the two major large multinational studies SOLIDARITY and DisCoVeRy concluded that there is no significant benefits. In my viewpoint, I can argue that the inconsistent time to initiate antiviral drug therapy during the course of the disease is the major contributing factor for this dilemma.

This article is protected by copyright. All rights reserved.